We explore recent biorobotics developments, including biohybrid lobster bots and a nature-inspired artificial eye, that will ...

PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Procept BioRobotics (Nasdaq:PRCT) announced that it received FDA investigational device exemption (IDE) for a second ...

Procept BioRobotics anticipates sharing the primary endpoint results from WATER IV in 2027.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Chicago Capital added 969,592 shares of PROCEPT BioRobotics, an estimated $27.32 million trade based on the average share price in the first quarter of 2026. Quarter-end position value rose by $16.57 ...

PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best robotic surgery stocks to buy. PROCEPT BioRobotics ...

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...